Mon, September 26, 2016
Fri, September 23, 2016
Thu, September 22, 2016
Wed, September 21, 2016
[ Wed, Sep 21st 2016 ] - Market Wire
Last Patient Out
Tue, September 20, 2016
Mon, September 19, 2016
Sun, September 18, 2016
Fri, September 16, 2016
Thu, September 15, 2016
Wed, September 14, 2016
Mon, September 12, 2016
Fri, September 9, 2016
Thu, May 9, 2013
[ Thu, May 09th 2013 ] - Market Wire
Achieves Record Revenues
Wed, May 8, 2013
Tue, May 7, 2013
Mon, May 6, 2013
Sun, May 5, 2013
Fri, May 3, 2013
Thu, May 2, 2013
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013
Sun, April 28, 2013
Fri, April 26, 2013
Thu, April 25, 2013
Wed, April 24, 2013
Tue, April 23, 2013
Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013

Depomed To Report First Quarter Fiscal Year 2013 Financial Results On Wednesday, May 8, 2013


//health-fitness.news-articles.net/content/2013/ .. 3-financial-results-on-wednesday-may-8-2013.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Depomed To Report First Quarter Fiscal Year 2013 Financial Results On Wednesday,... -- NEWARK, Calif., May 1, 2013 /PRNewswire/ --

NEWARK, Calif., May 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: [ DEPO ]) today announced that it will release first quarter fiscal year 2013 financial results after the market closes on Wednesday, May 8, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results.

Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at [ http://www.depomed.com ]. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN).  Zipsor ® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.  Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, [ www.depomed.com ].

CONTACT:
August J. Moretti  
Depomed, Inc.
650-462-5900
[ amoretti@depomed.com ]

 

SOURCE Depomed, Inc.



RELATED LINKS
[ http://www.depomed.com ]

Publication Contributing Sources